Perrigo

Perrigo Attains FDA Approval For Testosterone Gel

The pharmaceutical firm has landed approval from the agency for the product, designed to treat males with low testosterone levels.

Perrigo Co. announced that it has received U.S. Food and Drug Administration approval for its New Drug Application (NDA) for testosterone gel 1%. Perrigo's NDA included a bioequivalence study that compared its product to AbbVie's AndroGel 1%.

AndroGel® 1% (testosterone gel 1%) is indicated to treat adult males who have low or no testosterone. Annual sales were approximately $705 million annually, as measured by Symphony Health.

No votes yet

Ther-Rx, Perrigo Launch Gynazole-1 Single-dose Yeast Infection Treatment

The pharmaceutical packaging and product is indicated for local treatment of yeast infections in non-pregnant women.

Ther-Rx Corp., a women's health-focused pharmaceutical company and subsidiary of K-V Pharmaceutical Company (OTCQB Marketplace:  KVPHA/KVPHB), and Perrigo Company (Nasdaq: PRGO; TASE) announced today that Gynazole-1® (Butoconazole Nitrate Vaginal Cream USP, 2%), indicated for the local treatment of yeast infections (vulvovaginal candidiasis infections caused by Candida) in non-pregnant women1, is now available for prescribing.  Gynazole-1 is available at major national and regional retail pharmacy chains across the country.

No votes yet

Perrigo Announces Commercial Launch of Betamethasone Valerate Foam

The product is the generic equivalent of Luxiq foam, intended for treatment of scalp psoriasis.

The Perrigo Company announced that it has begun commercial shipments of betamethasone valerate foam 0.12%, the generic equivalent of Luxiq® Foam, consistent with the date certain launch settlement previously announced. Cobrek Pharmaceuticals, Inc., which was recently acquired by Perrigo, was first to file, making the product eligible for 180 days of marketing exclusivity. Perrigo is entitled to receive 100% of the profits from net sales of the product due to the Cobrek acquisition.

No votes yet

Perrigo Announces FDA Approval Of Betamethasone Valerate Foam 0.12%

The product, from the company’s partner firm Cobrek Pharmaceuticals Inc., is indicated for treatment of scalp psoriasis.

Perrigo Co. announced that its partner, Cobrek Pharmaceuticals, Inc., received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application (ANDA) for betamethasone valerate foam 0.12%, the generic equivalent of Luxiq Foam. Perrigo has manufactured the product and is preparing to commence commercial shipments on January 15, 2013, consistent with the date certain launch settlement. Cobrek was first to file, making the product eligible for 180 days of marketing exclusivity.

No votes yet

Perrigo to Launch Mini Nicotine Lozenges

The drug firm has received the go-ahead from the FDA to market the OTC smoking-cessation product.

The Perrigo Company today announced that it has received approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Applications (ANDA) to market over-the-counter nicotine polacrilex mini lozenge USP, 2 mg (mint flavor) and 4 mg (mint flavor).

Your rating: None Average: 5 (1 vote)

Perrigo Acne Gel Generic Receives FDA Approval

The gel is the generic equivalent of Duac Gel treatment for acne vulgaris.

Perrigo Company announced that it has received final approval from the U.S.

No votes yet
Syndicate content